Camptothecins in clinical development

Bibliography

• BAILLY C: Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem. (2000) 7:39–58.
   PubMed Web of Science ®Google Scholar
• POMMIER Y, POURQUIER P, FAN Y, STRUMBERG D: Mechanism of action of eukariotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta (1998) 1400:83–106.
   PubMed Web of Science ®Google Scholar
• LIU LF, DESAI SD, LI TK, MAO Y, SUN M, SIM SP: Mechanism of action of camptothecin. Ann. NY Acad. Sci. (2000) 922:1–10.
   PubMed Web of Science ®Google Scholar
• ZUNINO F, DALLAVALLE S, LACCABUE D, BERETTA G, MERLINI L, PRATESI G: Current status and perspectives in the development of camptothecins. Curr. Pharm. Des. (2002) 8:2505–2520.
   PubMed Web of Science ®Google Scholar
• WANG JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev Mol Cell. Biol. (2002) 3:430–440.
   PubMed Web of Science ®Google Scholar
• SORET J, GABUT M, DUPON C et al: Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in mammalian cells lacking topoisomerase I. Cancer Res. (2003) 63:8203–8211.
   PubMed Web of Science ®Google Scholar
• YAO S, MURALI D, SEETHARAMULU P et al.: Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I. Cancer Res. (1998) 58:3782–3786.
   PubMed Web of Science ®Google Scholar
• MILLER SE, PILCH DS: A spectrophotometric study of the pH-dependent and DNA binding properties of topotecan. Ann. NY Acad. Sci. (2000) 922:309.
   PubMed Web of Science ®Google Scholar
• STAKER BL, HJERRILD K, FEESE MD, BEHNKE CA, BURGIN AB, STEWART L: The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA (2002) 99:15387–15392.
   PubMed Web of Science ®Google Scholar
• ••Fundamental study on the structure of the ternary complex DNA-enzyme-camptothecin.
   Google Scholar
• PEREGO P, CAPRANICO G, SUPINO R, ZUNINO F: Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types. Anticancer Drugs (1994) 5:645–649.
   PubMed Web of Science ®Google Scholar
• DARZYNKIEWICZ Z, BRUNO S, DEL BINO G, TRAGANOS F: The cell cycle effects of camptothecin. Ann. NY Acad. Sci. (1996) 803:93–110.
   PubMed Web of Science ®Google Scholar
• POMMIER Y, GUPTA M, VALENTI M, NIEVES-NEIRA W: Cellular resistance to camtptothecins. Ann. NY Acad. Sci. (1996) 803:60–73.
   PubMed Web of Science ®Google Scholar
• DALLAVALLE S, MERLINI L, PENCO S,ZUNINO F: Perspective in camptothecin development. Expert Opin. Ther. Patents (2002) 12:837–844.
   Web of Science ®Google Scholar
• ULUKAN H, SWAAN PW: Camptothecins. A review of their chemotherapeutic potential. Drugs (2002) 62:2039–2057.
   Google Scholar
• BURKE TG, MI Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. Med. Chem. (1994) 37:40–46.
   Web of Science ®Google Scholar
• ••Study of the critical structural elements involved in drug interaction with human serum albumin.
   Google Scholar
• GARCIA-CARBONERO R, SOPKO JG: Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Cancer Res. (2002) 8:641–661.
   Web of Science ®Google Scholar
• PIZZOLATO JF, SALTZ LB: The camptothecins. Lancet (2003) 361:2235–2242.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review on the role of camptothecins in clinical therapy.
   Google Scholar
• CLARKE-PEARSON DL, VEN LE L, IVESON T et al.: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Oncol (2001) 19:3967–3975.
   Google Scholar
• KRUIJTZER CMF, BEIJNEN JH, ROSING H et al.: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. Oncol (2002) 20:2943–2950.
   Google Scholar
• HUDES G: Boosting bioavailability of topotecan: what do we gain?' Clin. Oncol (2002) 20:2918–2919.
   Google Scholar
• PEREGO P, DE CESARE M, DE ISABELLA P et al: A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res. (2001) 61:6034–6037.
   PubMed Web of Science ®Google Scholar
• ••First demonstration of the ability ofgirnatecan to overcome BCRP-mediated resistance.
   Google Scholar
• SPARREBOOM A, DANESI R, ANDO Y, CHAN J, FIGG WD: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist. Update (2003) 6:71–84.
   PubMed Web of Science ®Google Scholar
• •Up-to-date review on the relevance of transport systems in antitumor chemotherapy.
   Google Scholar
• ALLEN JD, SCHINKEL AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Ma Cancer Thar. (2002) 1:427–434.
   PubMed Web of Science ®Google Scholar
• PIZZOLATO JF, SALTZ LB: Irinotecan (Campto) in the treatment of pancreatic cancer. Expert Rev Anticancer Thar. (2003) 3:587–593.
   PubMedGoogle Scholar
• MORTON CL, WADKINS RM, DANKS MK, POTTER PM: The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. (1999) 59:1458–1463.
   PubMed Web of Science ®Google Scholar
• GUPTA E, LESTINGI TM, MICK R, RAMIREZ J, VOKES EE, RATAIN MJ: Metabolic fate or irinotecan in humans: correlations of glucuronidation with diarrhea. Cancer Res. (1994) 54:3723–3725.
   PubMed Web of Science ®Google Scholar
• XIE R, MATHIJSSEN RHJ, SPARREBOOM A, VERWEIJ J, KARLSSON MO: Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol Thar. (2002) 72:265–275.
   Web of Science ®Google Scholar
• DALLAVALLE S, FERRARI A, BIASOTTI B et al.: Novel 7-oxyiminomethyl derivatives of camptothecin with potent M vitro and in vivo antitumor activity. I Med. Chem. (2001) 44:3264–3274.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, MAROUN J, VANHOEFER U, VAN CUTSEM E: Optimizing the use of irinotecan in colorectal cancer. Oncologist (2001) 6:17–23.
   PubMed Web of Science ®Google Scholar
• AISNER J, MUSANTI R, BEERS S, SMITH S, LOCSIN S, RUBIN EH: Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Clin. Cancer Res. (2003) 9:2504–2509.
   PubMed Web of Science ®Google Scholar
• LICITRA EJ, VYAS V, NELSON K et al: Phase I evaluation of sequential topoisomerase targeting with irinotecan/ cisplatin followed by etoposide in patients with advanced malignancy. Clin. Cancer Res. (2003) 9:1673–1679.
   PubMed Web of Science ®Google Scholar
• ZEGHARI-SQUALLY N, RAYMOND E, CVITKOVIC E, GOLD WASSER F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin. Cancer Res. (1999) 5:1189–1196.
   PubMed Web of Science ®Google Scholar
• BOIGE V, RAYMOND E, FAIVRE S et al.: Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. Clin. Oncol (2000) 18:3986–3992.
   Web of Science ®Google Scholar
• ROYCE ME, HOFF PM, DUMAS P et al.: Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J. Clin. Oncol (2001) 19:1493–1500.
   PubMed Web of Science ®Google Scholar
• GILLES FJ, CORTES JE, THOMAS DAet al.: Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Gin. Cancer Res. (2002) 8:2134–2141.
   Google Scholar
• GARRISON MA, HAMMOND LA, GEYER CE et al.: A Phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. Gin. Cancer Res. (2003) 9:2527–2537.
   Web of Science ®Google Scholar
• ESTEVA FJ, RIVERA E, CRISTOFANILLI M et al.: A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer (2003) 98:900–907.
   PubMed Web of Science ®Google Scholar
• GAMUCCI T, PARIDAENS R, HEINRICH B et al.: Activity and toxicity of GI147211 in breast, colorectal and non- small-cell lung cancer patients: an EORTC-ECSG Phase II clinical study. Ann. Oncol (2000) 11:793–797.
   PubMed Web of Science ®Google Scholar
• LOOS WJ, KEHRER D, BROUWER E et al.: Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. Chromatogr. B. Biomed. Appl. (2000) 738:155–163.
   PubMedGoogle Scholar
• KEHRER DFS, BOS AM, VERWEIJ J et al.: Phase I and pharmacologic study of liposomal lurtotecan, NX2 U: urinary excretion predicts hematologic toxicity. Oncol (2002) 20:1222–1231.
   Google Scholar
• CALVERT AH, GRIMSHAW R, POOLE C et al.: Randomized Phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): an NCIC CTG study. Proc. Am. Soc. Gin. Oncol (2002) 21 (Abstract 830).
   Google Scholar
• LEE JH, LEE JM, LIM KH et al.: Preclinical and Phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann. NY Acad. Sci. (2000) 922:324–325.
   PubMed Web of Science ®Google Scholar
• SONG Y, SEO S-S, BANG Y-J et al.: Phase II evaluation of ckd-602, a camptothecin analog, administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer. Proc. Am. Soc. Oncol (2003) 22(Abstract 1877).
   Google Scholar
• LERCHEN HG, BAUMGARTEN J, VON DEM BRUCH K et al.: Design and optimization of 20-0-linked camptothecin glycocomjugates as anticancer agents. J. Med. Chem. (2001) 44:4186–4195.
   Google Scholar
• MROSS K, SAUER U, HARING B et al.: A Phase I dose scalation pharmacokinetic (PK) study of BAY 38–3441 administered as a short infusion once every three weeks. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 396).
   Google Scholar
• SIU LL, BATIST G, BANGASH N et al: A Phase I study of BAY 38–3441 given as a short infusion daily for five days every 3 weeks: a National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 395).
   Google Scholar
• CHATTERJEE A, DIGUMARTI R, MAMIDI RN et al: DRF-1042, a novel orally active camptothecin (CPT) analog: safety, pharmacokinetic (PK) and pharmacodynamic evaluation in a Phase I 281 Expert Op/n. lnvestig. Drugs (2004) 13(3) dose escalation study. Proc. Am. Soc. Clin. °flea (2002) 21(Abstract 384).
   Google Scholar
• VERSCHRAEGEN CF, NATELSON EA, GIOVANELLA BC et al.: A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs (1998) 9:36–44.
   PubMed Web of Science ®Google Scholar
• STEHLIN JS, GIOVANELLA BC, NATELSON EA et al.: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol (1999) 14:821–831.
   PubMed Web of Science ®Google Scholar
• MICHAELSON MD, RYAN DP, FUCHS CS et al.: A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Cancer (2003) 97:148–154.
   PubMed Web of Science ®Google Scholar
• RAJENDRA R, GOUNDER MK, SALEEM A et al.: Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. (2003) 63:3228–3233.
   PubMed Web of Science ®Google Scholar
• XIONG HQ, TRAN HT, MADDEN TL, NEWMAN RA, ABRUZZESE JL: Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. Clin. Cancer Res. (2003) 9:2066–2071.
   PubMed Web of Science ®Google Scholar
• LEGUIZAMO J, QUINN M, TAKIMOTO CH et al.: A Phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion. Cancer Chemother. Pharmacol (2003) 52:333–338.
   PubMed Web of Science ®Google Scholar
• BOM D, CURRAN DP, KRUSZEWSKI S, ZIMMER SG, STRODE JT, KOHLHAGEN G: The novel silatecan 7-tert-butyldimethylsily1-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. (2000) 43:3970–3980.
   PubMed Web of Science ®Google Scholar
• POLLACK IF, ERFF M, BOM D, BURKET G, STRODE JT, CURRAN DP: Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res. (1999) 59:4898–4905.
   PubMed Web of Science ®Google Scholar
• VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer (2000) 88:260–266.
   PubMed Web of Science ®Google Scholar
• VAN HATTUM AH, SCHLUPER HMM, HAUSHEER FH, PINEDO HM, BOVEN E: Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int. J. Cancer (2002) 100:22–29.
   PubMed Web of Science ®Google Scholar
• THOMPSON P, BERG S, GURURANGAN S et al.: A Phase I study of karenitecin in children. Proc. Am. Ass. Cancer Res. (2002) (Abstract 2748).
   Google Scholar
• DAUD A, BALAR B, VALKOV N et al.: Phase II trial of karenitecin, a novel topoisomerase I inhibitor in metastatic melanoma: clinical and translational study. Proc. Am. Soc. Clin. Oncol (2003) 22(Abstract 2871).
   Google Scholar
• HERNDON JE, MILLER AA, ZHANG C et al.: Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004. Proc. Am. Soc. Clin. Oncol (2003) 22(Abstract 2706).
   Google Scholar
• BAILLY C: Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. M Oncol Hematol (2003) 45:91–108.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on the mechanism of action of carnptothecins and homocarnptothecins.
   Google Scholar
• SCOTT LC, SOEPENBERG 0, TWELVES C et al: A pharmacological comparison of Phase I studies of diflomotecan (BN80915) administered orally and intravenously daily for 5 days every 3 weeks in patients with solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21(Abstract 534).
   Google Scholar
• GELDERBLOM H, SALAZAR R, VERWEIJ J et al.: Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-Ring-modified camptothecin analogue in adults with solid tumors. Clin. Cancer Res. (2003) 9:4101–4107.
   PubMed Web of Science ®Google Scholar
• DALLAVALLE S, DELSOLDATO T, FERRARI A et al.: Novel 7-substituted camptothecins with potent antitumor activity. I Med. Chem. (2000) 43:3963–3969.
   PubMed Web of Science ®Google Scholar
• DE CESARE M, PRATESI G, PEREGO P et al.: Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res. (2001) 61:7189–7195.
   PubMed Web of Science ®Google Scholar
• PRATESI G, DE CESARE M, CARENINI N et al.: Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin. Cancer Res. (2002) 8:3904–3909.
   PubMed Web of Science ®Google Scholar
• ZUCCHETTI M, PACE S, FRAPOLLI R et al.: Clinical pharmacokinetic profile of gimatecan (5T1481), a new derivative. Proc. Am. Soc. Clin. Oncol (2002) 21(Abstract 476).
   Google Scholar
• CROCE A, BOTTIROLI G, SUPINO R et al.: Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem. Pharmacol (2004) (In press).
   Google Scholar
• PETRANGOLINI G, PRATESI G, DE CESARE M et al: Antiangiogenic effects of the novel camptothecin 5T1481 (gimatecan) in human tumor xenografts. MM. Cancer Res. (2003) 1:863–870.
   PubMed Web of Science ®Google Scholar
• GIANNI L, HESS D, BASELGA J et al: A Phase I study of the oral camptothecin gimatecan with a design of cencerted dose escalation in three schedules of different dosing-duration. Proc. Am. Soc. Clin. Oncol (2003) 22(Abstract 554).
   Google Scholar
• ALDERSON L, SUPKO J, MAESTRI X et al. Phase I/II trial of gimatecan in patients with recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol (2003) 22:(Abstract 416).
   Google Scholar
• ZHU AX, READY NE, CLARK JVV et al.: Phase I trial of gimatecan given orally once a week for 3 or 4 weeks in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2003) 22(Abstract 557).
   Google Scholar
• SEYMOUR LW: Passive tumor targeting of soluble macromolecules drug conjugates. Grit. Rev Ther. Drug Carrier Sys. (1992) 9:135–187.
   PubMed Web of Science ®Google Scholar
• •Review documenting the physiological basis of the EPR effect.
   Google Scholar
• GREENWALD RB, CHOE YH, MCGUIRE J, CONOVER CD: Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deify. Rev (2003) 55:217–250.
   PubMed Web of Science ®Google Scholar
• ZHAO H, LEE C, SAI P et al: 20-0-acylcamptothecin derivatives: evidence for lactone stabilization. J. Org. Chem. (2000) 65:4601–4606.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, RIZZO J, OCHOA L et al.: A Phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. .I. Clin. Oncol (2003) 21:148–157.
   PubMed Web of Science ®Google Scholar
• SCHOEMAKER NE, VAN KESTEREN C, ROSING H et al: A Phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. .1. Cancer (2002) 87:608–614.
   PubMed Web of Science ®Google Scholar
• SARAPA N, BRITTO MR, SPEED W et al.: Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother. Pharmacol (2003) 52:424–430.
   PubMed Web of Science ®Google Scholar
• INOUE K, KUMAZAWA E, KUGA H, SUSAKI H, MASUBUCHI N, KAJIMURA T: CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv. Exp. Med. Biol. (2003) 519:145–153.
   PubMed Web of Science ®Google Scholar
• TAKIMOTO CHM, FORERO L, SCHWARTZ GH et al.: A Phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Proc. Am. Soc. Clin. Oncol (2003) 22(Abstract 522).
   Google Scholar
• SOEPENBERG 0, DE JONGE M, SPARREBOOM A et al.: Phase I and PK study of DE-310 (D) given once every 2 or 6 wks (w) in pts with solid tumors. Proc. Am. Soc. Gin. Oncol (2003) 22(Abstract 523).
   Google Scholar
• BHATT R, DE VRIES P, TULINSKY J et al.: Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 205-camptothecin. J. Med. Chem. (2003) 46:190–193.
   PubMed Web of Science ®Google Scholar
• SINGER JW, BHATT R, TULINSKY J et al.: Water-soluble poly-(Lglutamic acid)-gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control Release (2001) 74:243–247.
   PubMed Web of Science ®Google Scholar
• SINGER JW, DE VRIES P, BHATT R et al.: Conjugation of camptothecins to poly-(L-glutamic acid). Ann. NY Acad. Sci. (2000) 922:136–150.
   PubMed Web of Science ®Google Scholar
• KINGSBURY WD, BOEHM JC, JAKAS DR et al: Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase land antitumor activity. Med. Chem. (1991) 34:98–107.
   Web of Science ®Google Scholar
• KUNIMOTO T, NITTA K, TANAKA T et al.: Antitumor activity of 7-ethy1-10- [4-(1-piperidino)-1-piperidinolcarbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res. (1987) 47:5944–5947.
   PubMed Web of Science ®Google Scholar
• GIOVANELLA BC, HINZ HR, KOZIELSIK AJ, STEHLIN JS Jr, SILBER R, POTMESIL M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20- (S)-camptothecin. Cancer Res. (1991) 51:3052–3055.
   PubMed Web of Science ®Google Scholar
• MITSUI I, KUMAZAWA E, HIROTA Y et al.: A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. fpn. J. Cancer Res. (1995) 86:776–782.
   PubMedGoogle Scholar
• UPRETI VV, MAMIDI RNVS, KATNENI K, SRINIVAS NR: Quantitative determination of DRF-1042 in human plasma by HPLC: validation and application in clinical pharmacokinetics. Biomed. Chromatog. (2003) 17:385–390.
   PubMed Web of Science ®Google Scholar
• COLBERN GT, DYKES DJ, ENGBERS C et al.: Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Gin. Cancer Res. (1998) 4:3077–3082.
   Web of Science ®Google Scholar
• HAUSHEER F, HARIDAS K, ZHAO M et al.: Karenitecins (part II): a novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc. Am. A. Cancer Res. (1998) 39:(Abstract 2862).
   Google Scholar
• LAVERGNE 0, LESUEUR-GINOT L, PLA RODAS F et al: Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem. (1998) 41:5410–5419.
   PubMed Web of Science ®Google Scholar
• BATIST G, SIU L, MACLEAN M et al:NCIC CTG Ind. 134: a Phase I study of a novel glycoconjugated camptothecin (BAY 38–3441) given as a short infusion daily for five days every 3 weeks. Proc. Am. A. Cancer Res. (2001) 42:(Abstraet 2896).
   Google Scholar
• CAIOLFA VR, ZAMAI M, FIORINO A et al.: Polymer-bound camptothecin: initial biodistribution and antitumor activity studies. Control Release (2000) 65:105–119.
   PubMed Web of Science ®Google Scholar
• MINKO T, PARANJPE PV, LALLOO BQA et al.: Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitivie and multidrug-resistant human ovarian carcinoma cells. Cancer Chemothec Pharmacol (2002) 50:143–150.
   PubMed Web of Science ®Google Scholar
• SPEYER J, HOCHSTER H, WADLER S et al.: Effective first line therapy of ovarian cancer (OC) with cisplatin and prolonged topotecan infusion-a NY-GOG/ECOG Study. Proc. Am. Soc. Gin. Oncol (2000) 19:380a (Abstract).
   Google Scholar
• BOLIS G, SCARFONE G, SCIATTA C, PARAZZIN F: A Phase II study of topotecan (T), carboplatin (C) and paclitaxel (P) as front line treatment in suboptimal advanced epithelial ovarian cancer (AEOC). Proc. Am. Soc. ChB. Oncol (2000) 19:390a (Abstract).
   Google Scholar
• LYNCH T, HERNDON J, LYSS A et al.: Paclitaxel (P) + topotecan (T) + GCSF for previously untreated extensive small cell lung cancer (E-SCLC): preliminary analysis of cancer and leukaemia group B (CALGB) 9430. Proc. Am. Soc. Clin. Oncol (2000) 19:491a (Abstract).
   Google Scholar
• GRAY J, HAINSWORTH J, BURRIS H et al.: Paclitaxel, carboplatin, and topotecan in the treatment of small cell lung cancer: a Phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol (2000) 19:494a (Abstract).
   Google Scholar
• ARDIZZONI A, MANEGOLD C, DEBRUYNE C et al.: European organization for research and treatment of cancer (EORTC) 08957 Phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin. Cancer Res. (2003) 9:143–150.
   PubMed Web of Science ®Google Scholar
• MOK TS, WONG H, ZEE B et al: A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. Cancer (2002) 95:1511–1519.
   PubMed Web of Science ®Google Scholar
• RINALDI DA, LORMAND NA, BRIERRE JE et al.: A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma. Cancer (2002) 95:1274–1278.
   PubMed Web of Science ®Google Scholar
• BERAN M, ESTEY E, O'BRIEN S et al: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukaemia../. Clin. Oncol (1999) 17:2819–2830.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JT, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 355:1041–1047.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl. Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• MASUDA N, FUKUOKA M, NEGORO S et al.: Randomized trial comparing cisplatin and irinotecan versus cisplatin and vindesine versus irinotecan alone in advanced non-small cell lung cancer, a multicenter Phase III study. Proc. Am. Soc. Clin. Oncol (1999) 18:459a (Abstract).
   Google Scholar
• NIHO S, NAGAO K, NISHIWAKI Y et al.: Randomized multicenter Phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1999) 18:1897 (Abstract).
   Google Scholar
• NODA K, NISHIWAKA Y, KAWAHARA M. et al.: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl. J. Med. (2002) 346:85–91.
   Google Scholar
• BOKU N, OHTSU A, SHIMADA Yet al.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol (1999) 17:319–323.
   Google Scholar
• ASSERSOHN L, BROWN G, CUNNINGHAM D et al: Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann. Omni (2004) 15:64–69.
   Google Scholar
• ILSON DH, SALTZ L, ENZINGER P et al.: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.Clin. Oncol (1999) 17:3270–3275.
   Web of Science ®Google Scholar
• ROCHA LIMA CM, SAVARESE D, BRUCKNER H et al.: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol (2002) 20:1182–1191.
   PubMed Web of Science ®Google Scholar
• STATHOPOULOS GP, RIGATOS SK, DIMOPOULOS MA et al: Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter Phase II study by the Greek Cooperative Groups for Pancreatic Cancer. Ann. Oncol (2003) 14:388-394. Affiliation Franco Zuninot & Graziella Pratesi tAuthor for correspondence Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy Tel: +39 02 23902267; Fax: +39 02 23902692; E-mail: [email protected]
   Google Scholar